III Sessione: Approcio metodologico alla ricerca

Varese 10-11 Marzo 2016

Come interpretare i risultati degli studi di non inferiorità

(l'esempio dei DOACs)

Francesco Dentali Dipartimento di Medicina Clinica Università dell' Insubria, Varese

Conflitti di Interesse

Letture Protocolli di Ricerca Advisory Boards

- Bayer
- ·BMS/Pfizer
- Boheringer
- · Daiichi
- · Sanofi
- · Alfa Wasserman

Antefatto



PubMed ‡

Superiority vs Non-inferiority







PubMed

PubMed comprises more than 25 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

PubMed Commons



Featured comment - Mar 8

Metformin, sulphonylurea & type 2 diabetes: A Margulis & colleagues discuss challenges in survival study.


1.usa.gov/1VV6cVh

Using PubMed	F
PubMed Quick Start Guide	E
Full Text Articles	5
PubMed FAQs	Ē
PubMed Tutorials	<u>C</u>
New and Noteworthy]

More Resources
MeSH Database
Journals in NCBI Databases
Clinical Trials
E-Utilities (API)
LinkOut

Superiorità vs non-inferiorità


Pubmed Research




Premesse



Non esiste un trattamento standard




Esiste un trattamento standard



Studi Sperimentali


	Objective	Typical No. of Patients
Phase I	To explore possible toxic effects and determine tolerance of the intervention (and tolerated dose, if a drug study).	10 to 30
Phase II	To determine if treatment has a therapeutic effect or if there is any hope for benefits to outweigh the risks.	20 to 50
Phase III	To compare new treatment to the standard therapy or a control or placebo (if no standard therapy exists).	100 to 1000
Phase IV	To obtain long-term, large-scale information on morbidity and late effects (postmarketing study).	Hundreds or thousands

Studi Sperimentali




Differenza nel rischio di eventi

How do we change data interpretation?






Non superiority or Non Inferiority?





Non superiority or Non Inferiority?



La posizione dell'AIFA

"Condurre uno studio di non inferiorità o di equivalenza potrebbe rivelarsi utile quando si voglia valutare se un trattamento sia più sicuro rispetto a quello di riferimento, possa offrire dei vantaggi in termini di compliance o di costi, o ancora quando si vogliano mettere a confronto diversi dosaggi, formulazioni o vie di somministrazione di uno stesso farmaco".

The ethics of noninferiority trials

Silvio Garattini and Vittorio Bertele'1 rightly caution about the traps to be avoided in doing non-inferiority trials, but go too far in suggesting that such trials should be uniformly banned "because they are unethical". A good example of the appropriate use of a non-inferiority trial is the current research programmes to develop new drugs for treatment of drug-sensitive tuberculosis.

Internationally recommended regimens are highly effective, curing 95% or more of patients in clinical trials in a wide variety of settings.23 However, they require a minimum of three drugs which have significant side-effects and need to be given for at least 6 months. Improving on such high cure rates is almost impossible, but shortening treatment duration would improve completion rates and reduce both the time that patients are exposed to potentially toxic drugs and the cost of delivering tuberculosis chemotherapy in the developing world where resources are severely stretched-important medical and public-health goals.

It is impossible to prove that two treatment regimens have the same effect; there will always be some uncertainty surrounding estimates, and a small difference in effect size can never be excluded. However, the risks to patients in a properly done non-inferiority trial are no greater than those in a superiority trial. If non-inferiority designs were banned, there would be no prospect of shortening the duration of chemotherapy for patients with tuberculosis. And that would surely be unethical.

We are part of a consortium that is doing a noninferiority trial.

*Andrew J Nunn, Sarah K Meredith, Melvin K Spigelman, Ann M Ginsberg, Stephen H Gillespie ajn@ctu.mrc.ac.uk

MRC Clinical Trials Unit, London NW1 2DA, UK (AJN, SKM); Global Alliance for TB Drug Development, New York, NY, USA (MKS, AMG); and Centre for Medical Microbiology, Royal Free and University College Medical School, London, UK (SHG)

- Garattini S, Bertele' V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet 2007; 370: 1875-77.
- FoxW, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications.Int J Tuberc Lung Dis 1999; 3: S231-79.
- Jindani A. Nunn Al Enarson DA, Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-51.

Silvio Garattini and Vittorio Bertele' (Dec 1 p 1875)1 argue that noninferiority trials "have no ethical justification, since they do not offer any possible advantage...to patients". Their conclusion is based of ethic of physician or each pati

supersed tions.2 lowever, this ethic only world where resources for health care are endless and hence do not matter. Yet in a world of limited resources, this ethic can lead to unfair practices, with some patients getting full access to services and others getting none.2

Under resource scarcity, non-inferiority trials can therefore be ethical: if the tested treatment is cheaper, savings can be used to treat patients with other diseases who would otherwise be denied treatment. Thus, non-inferiority trials can help to increase population health. Even providing patients with slightly inferior interventions can be ethically justified if savings are substantial and help to treat other patients for a larger

Finally, it is true that the definition of the inferiority margin is arbitrary, but this certainly also applies to the significance level of α =0.05 in superiority trials.

I declare that I have no conflict of interest.

Afschin Gandjour afschin.gandlour@uk-koein.de Institute for Health Economics and Clinical Epidemiology, University of Cologne, 50935 Cologne, Germany

- Garattini S, Bertele V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet 2007; 370: 1875-77.
- Pearson SD. Caring and cost: the challenge for physician advocacy. AnnIntern Med 2000;

In their Viewpoint, Silvio Garattini and Vittorio Bertele' call on the scientific community to ban non-inferiority trials because they are unethical. If efficacy were the only advantage patients might get from clinical trials. I would agree. However, there is no doubt that increasing drug adherence by providing a combination pill, for example, or increasing availand affordability by drugs M

ere take examples gies that used non-inferiority designs to argue for their call to ban them. I believe that they confuse non-inferiority as a design with investigators' errors in using it. Setting wide inferiority limits or using statistical rather than clinical difference as a basis for concluding that a drug is noninferior are investigators' decisions, which are not necessarily right. The appropriate action would be to ban the improper application of the noninferiority design, not the design itself.

I declare that I have no conflict of interest.

Elsayed Z Soliman esoliman@wfubmc.edu

Epidemiological Cardiology Research Center (EPICARE), Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston Salem, NC 27 157, USA

Garattini S, Bertele V. Non-inferiority trials are unethical because they disregard patients' interests.Lancet 2007; 370: 1875-77.

Silvio Garattini and Vittorio Bertele'1 assert that "non-inferiority trials are unethical because they disregard patients' interest". This ignores the demonstrable and continuing value of non-inferiority trials. For example, since the introduction of cytotoxic http://ees.elsevier.com/ drugs against solid tumours and


Submissions should be submission system at

The printed iournal includes an image merely for illustration

Dimostrare che un trattamento antitubercolare di durata < 6 mesi è "non inferiore" ad un trattamento di durata 6 mesi permetterebbe di:

1) Evitare molti effetti collaterali 2) Ridurre i costi, utilizzando le (scarse) risorse per curare altri pazienti.

Warfarin in Atrial Fibrillation



WARFARIN SODIUM VERSUS LOW-DOSE HEPARIN IN THE LONG-TERM TREATMENT OF VENOUS THROMBOSIS

Russell Hull, M.B., B.S., Terry Delmore, M.Sc., Edward Genton, M.D., Jack Hirsh, M.D., Michael Gent, M.Sc., David Sackett, M.D., M.Sc., Dermot McLoughlin, M.B., B.S., and Peter Armstrong, M.D.

Abstract Acute deep-vein thrombosis is usually treated with intravenous heparin for a number of days, then with oral anticoagulants for weeks to months. We have compared adjusted-dose warfarin sodium with fixed low-dose subcutaneous heparin in the prevention of recurrent deep-vein thrombosis. Sixty-eight patients with acute deep-vein thrombosis confirmed by venography were treated with intravenous heparin and then randomized to secondary prophylaxis. Nine of 35 patients receiving subcutaneous heparin, but none of 33 receiving warfarin sodi-

um, had new episodes of objectively documented venous thromboembolism (P = 0.001). Seven patients on warfarin sodium experienced bleeding complications (of which four were major), as compared with no patients receiving subcutaneous heparin (P<0.005). Thus, adjusted-dose warfarin sodium is more effective than low-dose subcutaneous heparin in preventing recurrent venous thromboembolism, but its use is accompanied by a significant risk of bleeding. (N Engl J Med 301:855-858, 1979)

9/35 (25.7%) vs 0/33 (0%)

of venous thromboembolism. The evidence that oral anticoagulants are effective for this purpose is limited to one retrospective study in which it was reported that the frequency of recurrence was lower in patients treated with oral anticoagulants than in a group receiving no treatment. However, since both the initial diagnosis of venous thrombosis and the diagnosis of recurrent thrombosis were based on clinical criteria and the patients were not randomized, only limited conclusions can be drawn from this study.

It would be desirable to obtain more definitive information about the value of oral anticoagulant drugs in the prevention of recurrent venous thromboembolism, since their use is associated with bleeding complications in 5 to 10 per cent of patients.2 In addition, an alternative form of secondary prevention with a lower risk of bleeding would be attractive if it was effective in preventing recurrent venous thromboembolism. Low-dose subcutaneous heparin has proved to be effective in the primary prevention of venous thromboembolism in a number of well defined highrisk groups without inducing major bleeding,3 and this approach was therefore compared with oral anticoagulant therapy for the secondary prevention of venous thromboembolism. Our study sought to establish the relative effectiveness and safety of these treatments in patients with acute venous thrombosis.

strated acute deep-vein thrombosis. Venography was performed because deep-vein thrombosis was suspected or because "\$1-fibrinogen leg scanning or impedance plethysmography (IPG) was positive in patients who were being screened postoperatively. Venography was performed by the method of Rabinov and Paulin, using diagnostic criteria previously described.

Patients were excluded if they were pregnant, had active pepticuler disease, had a history of allergy to the dye used in venography or could not be followed as outpatients because of geographic inaccessibility; all exclusions were documented. Patients were stratified according to the site of thrombosis (proximal-vein thrombosis or calf only) and according to history of previous venous thromboembolism.

Regimens


All patients were treated for 14 days with continuous intravenous heparin that was adjusted to maintain the activated partial thromboplastin time at 11/2 to two times the normal control. Informed consent was obtained, and the patients were allocated at random on Day 10 (by use of a system of sealed envelopes) to receive either warfarin sodium or low-dose heparin. Warfarin sodium treatment began four days before stopping heparin in an initial dose of 10 mg per day. To avoid intervention by study physicians who might keep the warfarin sodium patients under closer supervision, anticoagulant control was monitored weekly with Simplastin (General Diagnostics) by each patient's family physician, who agreed to adjust the warfarin sodium dose to maintain the prothrombin time at 11/2 to two times the control value. Fixed, lowdose subcutaneous heparin was begun on Day 14 at a dose of 5000 units every 12 hours. The initial injections were carried out by the nursing staff and then by the patients under direct supervision. Upon discharge from hospital, patients were given a three- to six-week supply of heparin, which was subsequently administered either by the patients themselves or by visiting nurses in the occasional patient who was unable to measure accurately the heparin

Treatment with either warfarin sodium or low-dose heparin continued for 12 weeks in patients who had proximal-vein thrombosis and for six weeks in patients who had calf-vein thrombosis. To avoid contamination, aspirin-containing drugs, sulfin-pyrazone and dipyridamole were prohibited during the period of trial.

From the departments of Pathology, Medicine and Clinical Epidemiology and Biostatistics, McMaster University Medical Centre and Chedoke Hospital, Hamilton, Ontario (address reprint requests to Dr. Hull at the Department of Medicine, Room 3V39, McMaster University Medical Centre, 1200 Main St. W., Hamilton, Ontario L8S 419, Canada).

This work was supported by grants from the Province of Ontario and from the Ontario and Canadian Heart Foundations.

Combined therapy and major CV events



Slow onset/offset **Unpredictable response** of action Warfarin therapy has several **Numerous food-drug** Narrow therapeutic window interactions (INR range 2-3) limitations that make it difficult to use in **Numerous drug-drug Routine coagulation** interactions monitoring practice **Risk of Bleeding**

 Warfarin was #1 in 2003 and 2004 in the number of mentions of "deaths for drugs causing adverse effects in therapeutic use"

Frequent dose adjustments


• Warfarin caused 6% of the 702,000 ADEs treated in the ED/year; 17% required hospitalization

Complications

Studi Sperimentali di superiorità Calcolo del Sample Size

- Least relevant difference or the clinical significance
- Type 1 error (false positive) -> Statistical significance
- Type 2 error (false positive) -> Power

Studi Sperimentali




Differenza nel rischio di eventi

Studi Sperimentali di non inferiorità Calcolo del Sample Size

- · Maximum relevant difference
- Type 1 error (false positive) -> Statistical significance
- Type 2 error (false positive) -> Power

Studi Sperimentali



Differenza nel rischio di eventi


Come si fa a calcolare questo benedetto margine + \Delta \%??




Margine di non inferiorità

- Clinicamente rilevante ("utile")
- Pre-specificato
- Scelto in riferimento all'efficacia (o effetto) del trattamento attivo (di riferimento) in studi precedenti controllati da placebo
- Il margine può essere espresso come media, rapporto...

Scelta del limite peggiore dell'intervallo di confidenza per testare la non inferiorità




RELY: Stroke or systemic embolism



BID = 1 somministrazione ogni 12 ore

ITT vs on-treatment

Stroke and non-CNS Embolism



ITT or on-treatment?

- In a superiority trial, (aim is to decide if two treatments are different), an ITT analysis is generally conservative (inclusion of protocol violators and withdrawals usually tend to make the results from the 2 treatments more similar).
- For an equivalence or non-inferiority trial this effect is no longer conservative (any blurring of the difference between the treatments will increase the chance of finding noninferiority).

ITT or on-treatment?

- In a superiority trial per protocol analysis this approach may tend to enhance any difference between the treatments rather than diminishing it, because uninformative "noise" is removed.
- •In an equivalence or non- inferiority trial both types of analysis should be per- formed and equivalence or non-inferiority can only be established if both analyses support it.

Per valutare la non inferiorità è necessario:

·Rigoroso disegno sperimentale:

- -includere un popolazione sovrapponibile a quella dello studio di riferimento
- -un trattamento di provata efficacia con la stessa dose e per un analogo periodo di osservazione
- -Alta adesione (compliance) alla terapia (se nessuno prende la terapia sia nel gruppo A che nel gruppo B, è facile che il gruppo A risulti 'non inferiore' al gruppo B)
- -Una adeguata potenza statistica per ridurre la probabilità di escludere differenze clinicamente rilevanti


Quality of reports of Equivalence or Noninferiority RCT

	No. (%)		
Characteristics of the Trial	Noninferiority Reports (n = 116)	Equivalence Reports (n = 46)	All Reports (N = 162)
Noninferiority or equivalence margin reported	112 (96.6)	44 (95.7)	156 (96.3)
Justification of the choice of the margin	24 (20.7)	9 (19.6)	33 (20.4)
Statistical considerations	3 (2.6)	2 (4.3)	5 (3.1)
Clinical considerations or results of a previous study	13 (11.2)	5 (10.9)	18 (11.1)
Both statistical considerations and clinical considerations or results of a previous study	8 (6.9)	2 (4.3)	10 (6.2)
Sample size calculated	92 (79.3)	35 (76.1)	127 (78.4)
Sample size taking into account the noninferiority or equivalence margin	81 (69.8)	35 (76.1)	116 (71.6)
Presence of all the elements needed for recalculation	63 (54.3)	24 (52.2)	87 (53.7)
Analysis			
ITT or modified ITT	90 (77.6)	27 (58.7)	117 (72.2)
Per-protocol	74 (63.8)	35 (76.1)	109 (67.3)
Both per-protocol and ITT, or per-protocol and modified ITT	51 (44.0)	18 (39.1)	69 (42.6)
Statistical methods Results with a Cl	95 (81.9)	41 (89.1)	136 (84.0)

Consort Check-list for noninferiority trials

PAPER SECTION	Item	Descriptor	Reported on Page #
And topic TITLE & ABSTRACT	1	How participants were allocated to interventions (e.g., "random	Fage #
	-	allocation", "randomized", or "randomly assigned"),	
INTRODUCTION		specifying that the trial is a non-inferiority or equivalence trial.	
Background	2	Scientific background and explanation of rationale, including the rationale for using a non-inferiority or equivalence	
Background		design.	
METHODS	3	Eligibility criteria for participants (detailing whether participants in the	
Participants		non-inferiority or equivalence trial are similar to those in any trial(s)	
		that established efficacy of the reference treatment) and the settings and locations where the data were collected.	
Interventions	4	Precise details of the interventions intended for each group <i>detailing</i>	
interventione		whether the reference treatment in the non-inferiority or equivalence	
		trial is identical (or very similar) to that in any trial(s) that established	
		efficacy, and how and when they were actually administered.	
Objectives	5	Specific objectives and hypotheses, including the hypothesis concerning	
Outcomes	6	non-inferiority or equivalence. Clearly defined primary and secondary outcome measures detailing	
Cateomes		whether the outcomes in the non-inferiority or equivalence trial are	
		identical (or very similar) to those in any trial(s) that established	
		efficacy of the reference treatment and, when applicable, any	
		methods used to enhance the quality of measurements (e.g., multiple	
Sample size	7	observations, training of assessors). How sample size was determined detailing whether it was calculated	
Campie Size	· •	using a non-inferiority or equivalence criterion and specifying the	
		margin of equivalence with the rationale for its choice. When	
		applicable, explanation of any interim analyses and stopping rules (and	
	8	whether related to a non-inferiority or equivalence hypothesis).	
Randomization Sequence generation	8	Method used to generate the random allocation sequence, including details of any restrictions (e.g., blocking, stratification)	
Randomization	9	Method used to implement the random allocation sequence (e.g.,	
Allocation		numbered containers or central telephone), clarifying whether the	
concealment		sequence was concealed until interventions were assigned.	
Randomization	10	Who generated the allocation sequence, who enrolled participants, and	
Implementation Blinding (masking)	11	who assigned participants to their groups. Whether or not participants, those administering the interventions, and	
Billiding (masking)		those assessing the outcomes were blinded to group assignment. If	
		done, how the success of blinding was evaluated.	
Statistical methods	12	Statistical methods used to compare groups for primary outcome(s),	
		specifying whether a one or two-sided confidence interval approach	
		was used. Methods for additional analyses, such as subgroup analyses and adjusted analyses.	
RESULTS	13	Flow of participants through each stage (a diagram is strongly	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		recommended). Specifically, for each group report the numbers	
Participant flow		of participants randomly assigned, receiving intended treatment,	
-		completing the study protocol, and analyzed for the primary	
		outcome. Describe protocol deviations from study as planned, together with reasons.	
Recruitment	14	Dates defining the periods of recruitment and follow-up.	
Baseline data	15	Baseline demographic and clinical characteristics of each group.	
Numbers analyzed	16	Number of participants (denominator) in each group included in each	
		analysis and whether the analysis was "intention-to-treat" and/or alternative analyses were conducted. State the results in absolute	
		alternative analyses were conducted. State the results in absolute numbers when feasible (e.g., 10/20, not 50%).	
Outcomes and	17	For each primary and secondary outcome, a summary of results for each	
estimation		group, and the estimated effect size and its precision (e.g., 95%	
		confidence interval). For the outcome(s) for which non-inferiority or	
		equivalence is hypothesized, a figure showing confidence intervals and	
Ancillary analyses	18	margins of equivalence may be useful. Address multiplicity by reporting any other analyses performed,	
Andmary analyses	Ι '΄	including subgroup analyses and adjusted analyses, indicating	
		those pre-specified and those exploratory.	
Adverse events	19	All important adverse events or side effects in each intervention group.	
DISCUSSION	20	Interpretation of the results, taking into account the non-inferiority or	· · · · · · · · · · · · · · · · · · ·
Interpretation		equivalence hypothesis and any other study hypotheses, sources of potential bias or imprecision and the dangers associated with	
		multiplicity of analyses and outcomes.	

C'è 'non inferiorità' e 'non inferiorità'......



Differenza nel rischio di eventi

Conclusioni

· Disegno molto utilizzato ultimamente

Attenzione al Delta!

· Attenzione alla qualità!

Grazie per l'attenzione!?

